1. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Issue 7 (July 2018) Authors: Rosenfeld, Margaret; Wainwright, Claire E.; Higgins, Mark; Wang, Linda T.; McKee, Charlotte; Campbell, Daniel; Tian, Simon; Schneider, Jennifer; Cunningham, Steve; Davies, Jane C.; Harris, William; Mogayzel, Peter; McCoy, Karen; Milla, Carlos; Rubenstein, Ronald; Walker, Seth; Black, Philip; Mont... Journal: Lancet Issue: Volume 6:Issue 7(2018) Page Start: 545 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long-term safety of lumacaftor–ivacaftor in children aged 2–5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study. Issue 9 (September 2021) Authors: Hoppe, Jordana E; Chilvers, Mark; Ratjen, Felix; McNamara, John J; Owen, Caroline A; Tian, Simon; Zahigian, Rachel; Cornell, Alexandra G; McColley, Susanna A Journal: Lancet Issue: Volume 9:Issue 9(2021) Page Start: 977 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. Issue 10 (October 2020) Authors: Feig, Denice S; Donovan, Lois E; Zinman, Bernard; Sanchez, J Johanna; Asztalos, Elizabeth; Ryan, Edmond A; Fantus, I George; Hutton, Eileen; Armson, Anthony B; Lipscombe, Lorraine L; Simmons, David; Barrett, Jon F R; Karanicolas, Paul J; Tobin, Siobhan; McIntyre, H David; Tian, Simon Yu; Tomlinso... Journal: Lancet Issue: Volume 8:Issue 10(2020) Page Start: 834 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Issue 3 (March 2022) Authors: Sutharsan, Sivagurunathan; McKone, Edward F; Downey, Damian G; Duckers, Jamie; MacGregor, Gordon; Tullis, Elizabeth; Van Braeckel, Eva; Wainwright, Claire E; Watson, Danie; Ahluwalia, Neil; Bruinsma, Bote G; Harris, Christopher; Lam, Anna P; Lou, Yiyue; Moskowitz, Samuel M; Tian, Simon; Yuan, Jas... Journal: Lancet Issue: Volume 10:Issue 3(2022) Page Start: 267 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Issue 4 (April 2019) Authors: McNamara, John J; McColley, Susanna A; Marigowda, Gautham; Liu, Fang; Tian, Simon; Owen, Caroline A; Stiles, David; Li, Chonghua; Waltz, David; Wang, Linda T; Sawicki, Gregory S Journal: Lancet Issue: Volume 7:Issue 4(2019) Page Start: 325 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Issue 2 (February 2017) Authors: Konstan, Michael W; McKone, Edward F; Moss, Richard B; Marigowda, Gautham; Tian, Simon; Waltz, David; Huang, Xiaohong; Lubarsky, Barry; Rubin, Jaime; Millar, Stefanie J; Pasta, David J; Mayer-Hamblett, Nicole; Goss, Christopher H; Morgan, Wayne; Sawicki, Gregory S Journal: Lancet Issue: Volume 5:Issue 2(2017) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Issue 8 (10th May 2018) Authors: Bessonova, Leona; Volkova, Nataliya; Higgins, Mark; Bengtsson, Leif; Tian, Simon; Simard, Christopher; Konstan, Michael W; Sawicki, Gregory S; Sewall, Ase; Nyangoma, Stephen; Elbert, Alexander; Marshall, Bruce C; Bilton, Diana Journal: Thorax Issue: Volume 73:Issue 8(2018) Page Start: 731 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Long-term safety and efficacy of lumacaftor–ivacaftor therapy in children aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study. Issue 7 (July 2021) Authors: Chilvers, Mark A; Davies, Jane C; Milla, Carlos; Tian, Simon; Han, Zifei; Cornell, Alexandra G; Owen, Caroline A; Ratjen, Felix Journal: Lancet Issue: Volume 9:Issue 7(2021) Page Start: 721 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. Issue 10 (October 2020) Authors: Feig, Denice S; Donovan, Lois E; Zinman, Bernard; Sanchez, J J; Asztalos, Elizabeth; Ryan, Edmond A; Fantus, I G; Hutton, Eileen; Armson, Anthony B; Lipscombe, Lorraine L; Simmons, David; Barrett, Jon F R; Karanicolas, Paul J; Tobin, Siobhan; McIntyre, H David; Tian, Simon Yu; Tomlinson, George; ... Journal: Lancet Issue: Volume 8:Issue 10(2020) Page Start: 834 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Issue 7 (July 2017) Authors: Ratjen, Felix; Hug, Christopher; Marigowda, Gautham; Tian, Simon; Huang, Xiaohong; Stanojevic, Sanja; Milla, Carlos E; Robinson, Paul D; Waltz, David; Davies, Jane C Journal: Lancet Issue: Volume 5:Issue 7(2017) Page Start: 557 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗